Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

FDA Approves New Treatment Option For Patients With HER2-Positive Breast Cancer Who Have Progressed On Available Therapies

quotesTrastuzumab deruxtecan (Enhertu), a HER2-targeting antibody drug conjugate, will represent an import…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

First Opinion: PhRMA’s Talking Points Shouldn’t Derail The Pelosi Drug Pricing Bill

quotesKudos to Dr Peter Bach on responding to PhRMA talking points on drug pricing. I am all for R&D …quotes

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

PBM Middlemen Continue to Dodge Responsibility for Patient Suffering and Rising Drug Prices

quotesPBMs are getting more brazen in how they delay and deny cancer patients their oral drugs. Anyone in …quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

FDA Approves Drugs Faster Than Ever But Relies On Weaker Evidence, Researchers Find

quotesThe header for this subject states that while drug/biologic approvals have arrived faster at the FDA…quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

Comments

Veru's Experimental Drug Reduces Hot Flashes In Men In Mid-Stage Study

quotesHot flashes are a common consequence of hormonal therapy for prostate cancer and strategies to treat…quotes

member-photo

H. Jack West, MD

Associate Clinical Professor, Medical Oncology
Executive Director, Employer Services
City of Hope Comprehensive Cancer Center
Duarte, CA

Comments

Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study

quotesThe main limitation I see here is that we're increasingly looking for a wider range of potentially c…quotes

member-photo

Winston Wong, PharmD

President, W-Squared Group

Comments

Dana-Farber Cancer Institute Analyzes Clinical Pathway Use to Reduce Unwarranted Variation

quotesThis piece is a great example of a pathway program in process. Clinical pathways are not meant to b…quotes

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

quotesC-C Chemokine Receptors (CCR5 or CD195) are ubiquitous on immune cells and play a significant role i…quotes

member-photo

Jeff Patton, M.D.

CEO
Tennessee Oncology

Comments

First Opinion: Physicians Aren’t ‘Burning Out.’ They’re Suffering From Moral Injury

quotesI found this article both fascinating and enlightening. I had not thought of "burnout" in terms of …quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

ASCO Launches New Payment Reform Model to Transform Cancer Care Delivery and Enhance the Quality of Patient Care

quotesSo a tale of two cities.....it is interesting to compare the oncology alternative payment model to t…quotes

member-photo

William Harwin MD

Florida Cancer Specialists
President and Managing Partner

Comments

Memorial Sloan Kettering to Offer DigniCap® Scalp Cooling Device in New York Metro Area Locations

quotesAt Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics

Professor and Chair, Department of Radiation Oncology

Interim Director, Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Comments

Radiotherapy Can Be Used In Hard-to-treat Bladder Cancer

quotesRadiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit of a renaissance…quotes